Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells

Area of Science:

• Oncology
• Pharmacology

Background:

• Cholangiocarcinoma (bile duct cancer) has a poor prognosis, necessitating novel therapeutic strategies.
• HMG-CoA reductase inhibitors (statins) show anticancer potential in various diseases, but their efficacy in cholangiocarcinoma is unexplored.

Purpose of the Study:

• To investigate the therapeutic potential of statins for cholangiocarcinoma treatment.
• To evaluate the effects of statins on cholangiocarcinoma cell proliferation, cell cycle, and intracellular signaling pathways.

Main Methods:

• Human cholangiocarcinoma cell lines (HuCCT1, YSCCC) were treated with pitavastatin and atorvastatin.
• Cell proliferation was assessed, and cell cycle/apoptosis were analyzed using Flow Cytometry (FACS).
• Intracellular signaling was examined via Western blotting, focusing on MAPK pathway components.

Main Results:

• Statins significantly suppressed cholangiocarcinoma cell proliferation after 72-hour incubation.
• Statin treatment led to cell cycle arrest (G2M reduction) and apoptosis induction (sub-G1 increase).
• Western blotting revealed increased cleaved caspase-3 and decreased phosphorylated ERK (p-ERK), indicating apoptosis via MAPK pathway inhibition.
• Statins demonstrated additive antiproliferative effects when combined with gemcitabine, cisplatin, and 5-FU.

Conclusions:

• Statins induce apoptosis in cholangiocarcinoma cells by suppressing the MAPK pathway.
• Statins represent a potential new treatment option for cholangiocarcinoma.
• Statins may enhance the efficacy of existing chemotherapeutic agents in cholangiocarcinoma treatment.